Extrait

Phase I part: - To determine the maximum tolerated dose (MTD) and recommended dose (RD) of human L19IL2 in combination with gemcitabine in advanced solid tumour patients for whom gemcitabine is a suitable therapy according to the discretion of the principal investigator or in relapsed/refractory advanced pancreatic cancer patients after 1st line gemcitabine-containing therapy. Phase II part: - To investigate the anti-cancer activity of L19IL2 in combination with gemcitabine as measured by Clinical Benefit Response in chemotherapy-naïve patients with advanced pancreatic cancer.

Critère d'inclusion

• Histologically or cytologically confirmed solid cancer of any pathology or adenocarcinoma of the pancreas

Liens

• ictrp
• euctr